Our Pipeline AMG208 AMG319 AMG337 AMG745 AMG780 AMG820 AMG900 AMG102 AMG386 AMG479 Denosumab blinatumomab Aranesp Neulasta Neupogen Nplate Vectibix Prolia XGEVA
---

AMG 208
AMG 208 is a small molecule inhibitor of c-Met, which inhibits both ligand-dependent and ligand-independent c-Met activation. It is in phase 1 clinical trials being investigated as a cancer treatment.

Learn more about the science behind AMG 208

---

AMG 319
AMG 319 is an orally-administered small molecule inhibitor of PI3 Kinase δ. It is being investigated as a treatment for hematologic malignancies.

Learn more about the science behind AMG 319

---

AMG 337
AMG 337 is a selective inhibitor of c-Met, which inhibits multiple mechanisms of c-Met activation. It is being investigated as a cancer treatment.

Learn more about the science behind AMG 337

---

AMG 745
AMG 745 is a peptibody that inhibits myostatin. It is being investigated for its utility to inhibit muscle loss associated with a variety of diseases and conditions.

Learn more about the science behind AMG 745

---

AMG 780
AMG 780 is a fully human anti-angiopoietin antibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1 and Ang2. It is being investigated as a cancer treatment.

Learn more about the science behind AMG 745

---

AMG 820
AMG 820 is a fully human antibody that targets c-fms and decreases tumor associated macrophage ("TAM") function. It is in phase 1 clinical trials being investigated as a cancer treatment.

---

AMG 900
AMG 900 is an orally administered small molecule inhibitor of Aurora kinases A, B, and C. It maintains anti-cancer activity in several preclinical models that are resistant to other chemotherapies. It is in phase 1 clinical trials being investigated as a cancer treatment.

---

Dulanermin
(AMG 951)

Dulanermin is a recombinant human protein that targets death receptors 4 and 5 ("DR4" and "DR5") and induces apoptosis in sensitive tumor cells. It is being investigated as a cancer treatment. We are developing this molecule in collaboration with Genentech, a member of the Roche Group.

Learn more about the science behind Dulanermin

---

Conatumumab
(AMG 655)

Conatumumab is a fully human monoclonal antibody agonist that targets death receptor 5 ("DR5") and induces apoptosis in sensitive tumor cells. It is in phase 2 clinical trials being investigated as a cancer treatment.

Learn more about the science behind Conatumumab

---

Rilotumumab
(AMG 102)

Rilotumumab is a fully human monoclonal antibody that blocks the action of hepatocyte growth factor/scatter factor. It is in phase 2 clinical trials being investigated as a cancer treatment.

Learn more about the science behind Rilotumumab

---

Trebananib
(AMG 386)

Trebananib is a peptibody that binds to and inhibits angiopoietin 1 and 2. trebananib is in phase 3 clinical trials being investigated as a cancer treatment.

Learn more about the science behind Trebananib

---

Ganitumab
(AMG 479)

Ganitumab is a fully human monoclonal antibody antagonist of IGF-1 receptor. It is in clinical trials being investigated as a cancer treatment.

Learn more about the science behind Ganitumab

---

Talimogene laherparepvec
Talimogene laherparepvec is an oncolytic herpes simplex virus type 1 engineered to replicate selectively in tumor cells and to express granulocyte-macrophage colony-stimulating factor.

Upon injection into accessible tumors, the proposed mode of action includes:

a) Necrosis of injected tumors due to virus replication

b) Induction of immune response against tumor antigens, leading to an effect on uninjected lesions

Learn more about the science behind Talimogene laherparepvec

---

Blinatumomab
Blinatumomab (also known as AMG 103, or earlier MT103) is bispecific T cell engager (BiTE®) antibody directed against CD19 and CD3. It is being developed to redirect the body's own immune T cells (CD3 positive cells) against malignant B cells (CD19 positive cells). Main fields of clinical development are acute lymphoblastic leukemia (ALL) and B-Non-Hodgkin's lymphoma (B-NHL).

---

Aranesp
Aranesp® (darbepoetin alfa) is a recombinant human protein agonist of the erythropoietin receptor.

Aranesp®

Learn more about the science behind Aranesp

---

Neulasta
Neulasta® (pegfilgrastim) is a leukocyte growth factor developed to decrease the incidence of infection, as manifested by febrile neutropenia, in patients diagnosed with non-myeloid malignancies who are undergoing treatment with myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

Neulasta®

Learn more about the science behind Neulasta

---

Neupogen
Neupogen® (Filgrastim) was developed as a treatment for reducing the incidence of infection from chemotherapy-induced neutropenia in cancer patients diagnosed with non-myeloid malignancies.

Neupogen®

Learn more about the science behind Neupogen

---

Nplate
Nplate® (romiplostim) is a peptibody agonist of the thrombopoietin (TPO) receptor.

Nplate®

Learn more about the science behind Nplate

---

Vectibix
Vectibix® (panitumumab) is a monoclonal antibody antagonist of the epidermal growth factor receptor ("EGFr") pathway. It is being investigated as a cancer treatment.

Vectibix®

Learn more about the science behind Vectibix

---

Prolia
Prolia® (denosumab) was developed as a treatment for patients suffering from bone loss due to hormonal cancer treatment in prostate and breast cancer at increased risk of fractures.

Prolia®

Learn more about the science behind Prolia

---

XGEVA
XGEVA® (denosumab) is a fully human monoclonal antibody developed for the prevention of skeletal-related events in adult patients with bone metastases from solid tumors. XGEVA® specifically inhibits RANK Ligand, a key mediator of cancer-induced bone destruction.

XGEVA®

Learn more about the science behind XGEVA

HomeAmgen.comAmgen MedInfoSitemapPrivacy PolicyContact Us
By clicking here, you will be
leaving Amgen Oncology International